2023 Indonesian Guidelines for Heart Failure Treatment: Working Group on Heart Failure and Cardiometabolic Diseases, Indonesian Heart Association
Third Edition
Abstract
Heart failure is a health problem with high mortality and morbidity rates in developed and developing countries such as Indonesia. The prevalence of heart failure itself is increasing because patients who experience acute heart failure can progress to chronic heart failure. Guidelines-Directed Medical Therapy (GDMT) with recommended doses is still underutilized in heart failure patients with reduced ejection fraction (HFrEF). In Indonesia itself, even though it has a fairly high rate of use of ACE-inhibitors (ACE-I) or angiotensin receptor blockers (ARB), Indonesia has the lowest rate of use of β-blockers and aldosterone inhibitors (also called Mineralocorticoid Receptor Antagonists, MRA) of the entire ASIAN-HF registry.84
Therefore, the writing of this guideline was carried out as an effort to provide practical guidance regarding the diagnosis, assessment and management of acute and chronic heart failure. Thus, it is hoped that efforts can be made to prevent the increase in prevalence and reduce the number of rehospitalization with complete management.
This book was written as an update to the 2020 Guideline for the Management of Heart Failure: Indonesian Heart Association. The sources of our updates came from many references and literatures carried out by each contributor and reviewed by EBM team.
Downloads
References
2. Aggarwal M, Bozkurt B, Panjrath G, et al. Lifestyle Modifications for Preventing and Treating Heart Failure. Journal of the American College of Cardiology. 2018;72(19):2391-2405.
3. American Association of Sleep Medicine. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, terminology and technical specifications. V2.5. April 2018.
4. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461.
5. Antariksa B. Patogenesis, diagnostik dan skrining OSA (obstructive sleep apnea). Jurnal Respirologi Indonesia. 2010.
6. Arter JL, Chi DS, M G, Fitzgerald SM, Guha B, Krishnaswamy G. Obstructive sleep apnea, inflammation, and cardiopulmonary disease. Front Biosci. 2004;9:2892-2900.
7. Arzt M, Obermeier R. Obstruktive Schlafapnoe bei Herzinsuffizienz. Somnologie - Schlafforschung und Schlafmedizin. 2010;14(1):48-55.
8. Bauersachs J, Veltmann C. Heart rate control in heart failure with reduced ejection fraction: the bright and the dark side of the moon. European journal of heart failure. 2020;22(3):539-42.
9. Bauters F, Rietzschel ER, Hertegonne KB, Chirinos JA. The Link Between Obstructive Sleep Apnea and Cardiovascular Disease. Curr Atheroscler Rep. 2016;18(1):1.
10. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid M, Adamopulos S, Albert N, et al. Consensus Statement Universal Definition and Classification of Heart Failure, A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. Journal of Cardiac Failure Vol. 27, No. 4. 2021
11. Butzner M, Riello III RJ, Sarocco P and Desai NR. Adverse Drug Effects Across Patients With Heart Failure: A Systematic Review. American Journal of Managed Care. 2022;28.
12. Cahyono A, Hermani B, Mangunkusumo E, Perdana RS. Hubungan Obstructive Sleep Apnea dengan Penyakit Sistem Kardiovaskuler. Oto Rhino Laryngologica Indonesiana. 2011;41(1):37-45.
13. Chung F, Yang Y, Brown R, Liao P. Alternative scoring models of STOP-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea. J Clin Sleep Med. 2014;10(9):951-958.
14. Crisci G, De Luca M, D’Assante R, et al. Effects of exercise on heart failure with preserved ejection fraction: an updated review of literature. J Cardiovasc Dev Dis. 2022;9(8):241.
15. Cunha FM, Pereira J, Marques P, Ribeiro A, Bettencourt P, Lourenço PJJoCM. Diabetic patients need higher furosemide doses: a report on acute and chronic heart failure patients. Journal of Cardiovascular Medicine 2020;21(1):21-26.
16. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008;29:2388–442.
17. Díez-Villanueva P, Alfonso F. Heart failure in the elderly. J Geriatr Cardiol. 2016;13(2):115-117.
18. Dokainish H, Nguyen JS, Sengupta R, Pillai M, Alam M, Bobek J, Lakkis N. Do additional echocardiographic variables increase the accuracy of e/e’ for predicting left ventricular filling pressure in normal ejection fraction? An echocardiographic and invasive hemodynamic study. J Am Soc Echocardiogr. 2010; 23:156–161.
19. Fukuta H, Goto T,Wakami K, Kamiya T, Ohte N. Effects of exercise training on cardiac function, exercise capacity, and quality of life in heart failure with preserved jection fraction: a meta-analysis of randomized controlled trials. Heart Fail Rev. 2019; 24(4):535-547.
20. Girerd N, Leclercq C, Hanon O, Bayés-Genís A, Januzzi JL, Damy T, Lequeux B, Meune C, Sabouret P and Roubille F. Optimisation of treatments for heart failure with reduced ejection fraction in routine practice: a position statement from a panel of experts. Revista Española de Cardiología (English Edition). 2023.
21. Girerd N, Seronde M-F, Coiro S, Chouihed T, Bilbault P, Braun F, Kenizou D, Maillier B, Nazeyrollas P and Roul G. Integrative assessment of congestion in heart failure throughout the patient journey. JACC: Heart Failure. 2018;6:273-285.
22. Gonzaga C, Bertolami A, Bertolami M, Amodeo C, Calhoun D. Obstructive sleep apnea, hypertension and cardiovascular diseases. Journal of Human Hypertension. 2015;29(12):705-712.
23. Government Q. Polysomnography Set-up (Adult Patients) Sleep Science. In. Queensland: Queensland Health; 2013:6.
24. Greene SJ, Bauersachs J, Brugts JJ, et al. Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions. Journal of the American College of Cardiology. 2023: 81; 4.
25. Greene SJ, Butler J and Metra M. Another reason to embrace quadruple medical therapy for heart failure: medications enabling tolerance of each other. 2021;23:1525-1528.
26. Guerra F, Brambatti M, Matassini MV, Capucci A. Current Therapeutic Options for Heart Failure in Elderly Patients. BioMed Research International. 2017;2017:1483873.
27. Gustafsson F, Arnold JMO. Heart failure clinics and outpatient management: review of the evidence and call for quality assurance. European Heart Journal 2004;25(18):1596-1604.
28. Ha JW, Andersen OS, Smiseth OA. Diastolic Stress Test: Invasive and Noninvasive Testing. JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 2):272-282. doi: 10.1016/j.jcmg.2019.01.037. Epub 2019 Jun 12. PMID: 31202741.
29. Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. The New England journal of medicine. 2020;383(15):1436-46.
30. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Praqctice Guidelines. Circulation. 145:e895-e1032, 2022.
31. Holty J-EC, Guilleminault C. Surgical Options for the Treatment of Obstructive Sleep Apnea. 2010;94(3):479-515.
32. Javaheri S. Effects of Continuous Positive Airway Pressure on Sleep Apnea and Ventricular Irritability in Patients With Heart Failure. Circulation. 2000;101(4):392-397.
33. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine. 2017;13(03):479-504.
34. Kasner M, Westermann D, Steendijk P, Gaub R, Wilkenshoff U, Weitmann K, Hoffmann W, Poller W, Schultheiss HP, Pauschinger M, Tschope C. Utility of doppler echocardiography and tissue doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: A comparative doppler-conductance catheterization study. Circulation. 2007; 116:637–647.
35. Kitzman DW, Brubaker P, Morgan T, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2016;315(1):36-46.
36. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374(9704):1840-8.
37. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, et al. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384(9961):2235-43.
38. Książczyk M and Lelonek M. Angiotensin receptor/neprilysin inhibitor—a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings. Heart failure reviews. 2020;25:393-402.
39. Lund LH, Claggett B, Liu J, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018;20(8):1230-1239.
40. Lyons OD, Bradley TD. Heart Failure and Sleep Apnea. Canadian Journal of Cardiology. 2015;31(7):898-908.
41. Madani M. Snoring and obstructive sleep apnea. Arch Iran Med. 2007;10(2):215-226.
42. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: β-blocker dose, heart rate reduction, and death in patients with heart failure. Annals of Internal Medicine 2009;150(11):784-794.
43. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, Group ESD. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal 2021;42(36):3599-3726.
44. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 00, 1 – 128. 2021, 2021.
45. McMurray JJ. Major beta blocker mortality trials in chronic heart failure: a critical review. Heart 1999;82 Suppl 4(Suppl 4):Iv14-22.
46. McMurray JJ, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MSJEjohf. The Dapagliflozin and Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial: baseline characteristics. European journal of heart failure 2019;21(11):1402-1411.
47. McMurray JJV, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart. European Heart Journal. 2012;33(14):1787-1847.
48. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz M, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg KJEjohf. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM‐HF). European journal of heart failure 2014;16(7):817-825.
49. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, Metra M, Ponikowski P, Sliwa K and Voors AA. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. The Lancet. 2022;400:1938-1952.
50. Mende CW. Chronic kidney disease and SGLT2 inhibitors: a review of the evolving treatment landscape. Advances in Therapy. 2022:1-17.
51. Metra M, Tomasoni D, Adamo M, et al. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2023.
52. Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging. 2012;16(7):601-608.
53. Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology. European journal of heart failure. 2020;22(4):584-603.
54. Mullens W, Martens P, Testani JM, Tang WW, Skouri H, Verbrugge FH, Fudim M, Iacoviello M, Franke J and Flammer AJ. Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. European journal of heart failure. 2022;24:603-619.
55. Naughton MT, Kee K. Sleep apnoea in heart failure: To treat or not to treat? Respirology. 2017;22(2):217-229.
56. Obokata M, Reddy YNV, Borlaug BA. The Role of Echocardiography in Heart Failure with Preserved Ejection Fraction: What Do We Want from Imaging? Heart Fail Clin. 2019 Apr;15(2):241-256. doi: 10.1016/j.hfc.2018.12.004. Epub 2019 Feb 2. PMID: 30832815; PMCID: PMC6402610.
57. Ouwerkerk W, Teng THK, Tromp J, Tay WT, Cleland JG, van Veldhuisen DJ, Dickstein K, Ng LL, Lang CC, Anker SD. Effects of combined renin–angiotensin–aldosterone system inhibitor and beta‐blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT‐CHF and ASIAN‐HF registries. European Journal of Heart Failure 2020;22(8):1472-1482.
58. Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass MJC. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Circulation 2021;143(4):326-336.
59. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. The New England journal of medicine. 2020;383(15):1413-24.
60. Packer M and McMurray JJ. Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction. European Journal of Heart Failure. 2021;23:882-894.
61. Pascual-Figal D, Wachter R, Senni M, Bao W, Noè A, Schwende H, Butylin D, Prescott MF, Gniot J, Mozheiko M, Lelonek M, Dominguez AR, Horacek T, Rio EGd, Kobalava Z, Mueller CE, Cavusoglu Y, Straburzynska-Migaj E, Slanina M, Dahl Jv, Senni M, Ryding A, Moriarty A, Robles MB, Villota JN, Quintana AG, Nitschke T, Pinilla JMG, Bonet LA, Chaaban S, zaatari SF, Spinar J, Musial W, Abdelbaki K, Belohlavek J, Fehske W, Bott MC, Hoegalmen G, Leiro MC, Ozcan IT, Mullens W, Kryza R, Al-Ani R, Loboz-Grudzien K, Ermoshkina L, Hojerova S, Fernandez AA, Spinarova L, Lapp H, Bulut E, Almeida F, Vishnevsky A, Belicova M, Pascual D, Witte K, Wong K, Droogne W, Delforge M, Peterka M, Olbrich H-G, Carugo S, Nessler J, McGill TH, Huegl B, Akin I, Moreira I, Baglikov A, Thambyrajah J, Hayes C, Barrionuevo MR, Yigit Z, Kaya H, Klimsa Z, Radvan M, Kadel C, Landmesser U, Tano GD, Lisik MB, Fonseca C, Oliveira L, Marques I, Santos LM, Lenner E, Letavay P, Bueno MG, Mota P, Wong A, Bailey K, Foley P, Hasbani E, Virani S, Massih TA, Al-Saif S, Taborsky M, Kaislerova M, Motovska Z, Cohen AA, Logeart D, Endemann D, Ferreira D, Brito D, Kycina P, Bollano E, Basilio EG, Rubio LF, Aguado MG, Schiavi LB, Zivano DF, Lonn E, Sayed AE, Pouleur A-C, Heyse A, Schee A, Polasek R, Houra M, Tribouilloy C, Seronde MF, Galinier M, Noutsias M, Schwimmbeck P, Voigt I, Westermann D, Pulignano G, Vegsundvaag J, Antunes JADS, Monteiro P, Stevlik J, Goncalvesova E, Hulkoova B, Fernandez AJC, Davies C, Squire I, Meyer P, Sheppard R, Sahin T, Sochor K, Geeter GD, Wachter R, Schmeisser A, Weil J, Soares AO, Vasilevna OB, Oshurkov A, Sunderland SJ, Glover J, Exequiel T, Decoulx E, Meyer S, Muenzel T, Frioes F, Arbolishvili G, Tokarcikova A, Karlstrom P, Vila JCT, Perez GP, Sankaranarayanan R, Nageh T, Alasia DC, Refaat M, Demirkan B, Al-Buraiki J, Karabsheh S. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction. 2020;8(10):822-833.
62. Patibandla S, Heaton J, Kyaw H. Spironolactone. In. StatPearls: StatPearls Publishing; 2021.
63. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation. 2015;131(1):34-42.
64. Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019 Oct 21;40(40):3297-3317. doi: 10.1093/eurheartj/ehz641. Erratum in: Eur Heart J. 2021 Mar 31;42(13):1274. PMID: 31504452.
65. Pitt B, Pfeffer MA, Assmann SF, et al; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370 (15):1383-1392.
66. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. The New England journal of medicine. 1999;341(10):709-17.
67. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2016;37(27):2129-2200.
68. Ramar K, Dort LC, Katz SG, et al. Clinical Practice Guideline for the Treatment of Obstructive Sleep Apnea and Snoring with Oral Appliance Therapy: An Update for 2015. Journal of Clinical Sleep Medicine. 2015;11(07):773-827.
69. Reyes EB, Ha JW, Firdaus I, et al. Heart failure across Asia: same healthcare burden but differences in organization of care. International Journal of Cardiology 223 (2016) 163-167.
70. Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. European Heart Journal. 2010;31(6):703-711.
71. Rosano GM, Moura B, Metra M, Böhm M, Bauersachs J, Ben Gal T, Adamopoulos S, Abdelhamid M, Bistola V and Čelutkienė J. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. European journal of heart failure. 2021;23:872-881.
72. Rosano GMC, Tamargo J, Kjeldsen KP, Lainscak M, Agewall S, Anker SD, et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. European heart journal Cardiovascular pharmacotherapy. 2018;4(3):180-8.
73. Shen L, Jhund PS, Docherty KF, Vaduganathan M, Petrie MC, Desai AS, Køber L, Schou M, Packer M and Solomon SD. Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal. 2022;43:2573-2587.
74. Shepertycky MR, Banno K, Kryger MH. Differences between men and women in the clinical presentation of patients diagnosed with obstructive sleep apnea syndrome. Sleep. 2005;28(3):309-314.
75. Singhania N, Bansal S, Mohandas S, Nimmatoori DP, Ejaz AA, Singhania G. Role of renin-angiotensin-aldosterone system inhibitors in heart failure and chronic kidney disease. Drugs Context 2020;9.
76. Singh KD, Karnik SSJCdt. Angiotensin type 1 receptor blockers in heart failure. Current drug targets 2020;21(2):125-131.
77. Siswanto BB, Hersunarti N, Erwinanto, Barack R, Nauli SE, Lubis AC, Wiryawan N, Dewi PP, Pratikto RS, Hasanah DY. 2020. Pedoman Tata Laksana Gagal Jantung: Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. Jakarta: PP PERKI.
78. Solomon SD, Claggett B, Lewis EF, et al; TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37(5):455-462.
79. Solomon SD, McMurray JJV, Anand IS, et al; PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609-1620.
80. Solomon SD, McMurray JJV, Claggett B, et al; DELIVER Trial Committees and Investigators.Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-1098.
81. Sorimachi H, Obokata M, Omote K, et al. Long-term changes in cardiac structure and function following bariatric surgery. J AmColl Cardiol. 2022;80(16):1501-1512
82. Stewart MG, Witsell DL, Smith TL, Weaver EM, Yueh B, Hannley MT. Development and validation of the Nasal Obstruction Symptom Evaluation (NOSE) scale. Otolaryngol Head Neck Surg. 2004;130(2):157-163.
83. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi LJTL. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. The Lancet 2010;376(9744):875-885.
84. Teng THK, Tromp J, Tay WT, et al. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. Lancet Glob Health 2018; 6: e1008-18.
85. Tromp J, Ouwerkerk W, van Veldhuisen DJ, Hillege HL, Richards AM, van der Meer P, Anand IS, Lam CS and Voors AA. A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction. Heart Failure. 2022;10:73-84.
86. Tromp J, Tay WT, Ouerkerk W, et al. Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. PLos Med 15(3): e1002541. 2018.
87. Vardeny O, Claggett B, Kachadourian J, Desai AS, Packer M, Rouleau J, Zile MR, Swedberg K, Lefkowitz M and Shi V. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM‐HF trial. European journal of heart failure. 2019;21:337-341.
88. Vest AR, Chan M, Deswal A, et al. Nutrition, Obesity, and Cachexia in Patients With Heart Failure: A Consensus Statement from the Heart Failure Society of America Scientific Statements Committee. J Card Fail. 2019;25(5):380-400
89. von Olshausen G, Benson L, Dahlström U, Lund LH, Savarese G, Braunschweig F. Catheter ablation for patients with atrial fibrillation and heart failure: insights from the Swedish Heart Failure Registry. Eur J Heart Fail. 2022;24(9):1636-1646.
90. Voors AA, Mulder H, Reyes E, Cowie MR, Lassus J, Hernandez AF, Ezekowitz JA, Butler J, O'Connor CM, Koglin JJEjohf. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. 2021;23(8):1313-1321.
91. Welch KC, Goldberg AN. Sleep Disorder. In: Lalwani AK, ed. Current Diagnosis & Treatment in Otolaryngology - Head & Neck Surgery 3rd Ed. 2012/05/29 ed.: Cambridge University Press; 2011:557-564.
92. Won CHJ, Li KK, Guilleminault C. Surgical Treatment of Obstructive Sleep Apnea: Upper Airway and Maxillomandibular Surgery. Proceedings of the American Thoracic Society. 2008;5(2):193-199.
93. Writing C, Maddox TM, Januzzi JL, Jr., Allen LA, Breathett K, Butler J, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2021;77(6):772-810.
94. Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Card Fail. 2022 May;28(5):e1-e167. doi: 10.1016/j.cardfail.2022.02.010. Epub 2022 Apr 1. PMID: 35378257.
95. Yacoub M, Youssef I, Salifu MO, McFarlane SI. Cardiovascular Disease Risk in Obstructive Sleep apnea: An Update. J Sleep Disord Ther. 2017;7(1):283.
96. Yumuk V, Tsigos C, Fried M, et al. European Guidelines for Obesity Management in Adults. Obesity Facts. 2015;8(6):402-424.
97. Yusuf S, Pfeffer MA, Swedberg K, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet. 2003;362(9386): 777-781.
PDF downloads: 74
Copyright (c) 2024 Indonesian Journal of Cardiology

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).